| Public | OTCBB:BMOD |
| Website | biomoda.com |
| Category | BioTech |
| Phone | 505.821.0875 |
| askbiomoda@biomod... | |
| Employees |
| TOTAL | $1M |
| VENTURE FUNDING TOTAL | $1M |
| Venture Round, 3/10 Hudson Bay Capital Management Ramius Iroquois Capital | $1M |
Biomoda, Inc., a development state company, operates as an invitro diagnostics company that develops assays or tests to detect cancer. The company’s non-invasive diagnostic is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. It also involves in developing collection protocol and diagnostics for other cancers, including breast, oral, prostate, bladder, colorectal, and cervical. The company has an agreement with the New Mexico Institute of Mining and Technology through the New Mexico Department of Veterans Services for a clinical study for the early detection of lung cancer of the state’s veterans. In addition, it has a collaborative agreement with Medical Acoustics, LLC to purchase its Lung Flute as part of the collection protocol in a clinical study. Further, the company has contracts with Quintiles Consulting and Alquest, Inc. who help to guide Biomoda through the FDA approval process. It has a strategic relationship with Obio. The company was founded in 1990 and is headquartered in Albuquerque, New Mexico.
